| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |